Orexigen Therapeutics Shares Plunged: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Orexigen Therapeutics (Nasdaq: OREX  ) fell 10% today after a Food and Drug Administration announcement.

So what: The FDA said weight-loss pill Contrave indeed helped patients lose weight but didn't meet all the requirements. The pill may cause heart health risks, and the FDA will have a panel vote on the drug Tuesday.

Now what: Two other weight-loss drugs have been rejected by the FDA, and Contrave is now coming into question. Investors may want to wait until after Tuesday's decision to reassess this stock. We could be in for another pummeling if the panel doesn't vote favorably.

Interested in more info on Orexigen Therapeutics? Add it to your watchlist.

Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1388970, ~/Articles/ArticleHandler.aspx, 12/19/2014 10:15:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement